The U.S. Department of Health and Human Services Office of Inspector General (HHS-OIG) has issued a sharp reminder to the healthcare industry: following the letter of one law does not grant immunity from another. In a series of updates to its fraud and abuse FAQs released on April 23, 2026, the agency moved to dismantle two of the most persistent myths in healthcare compliance—the belief that satisfying the Stark Law eliminates Anti-Kickback Statute (AKS) risk, and the idea that paying “fair market value” is a foolproof shield against kickback allegations.
For years, healthcare providers and administrators have often treated compliance as a checklist. The logic was simple: if a financial arrangement met the strict requirements of a Stark Law exception or if the payment was backed by a Fair Market Value (FMV) appraisal, the arrangement was deemed “safe.” The OIG’s latest guidance, specifically through a revised FAQ No. 4 and a brand-new FAQ No. 17, clarifies that this approach is fundamentally flawed and potentially dangerous for organizations facing federal scrutiny.
These updates do not create new laws, but they signal a rigorous enforcement posture. By explicitly stating that FMV and Stark compliance are not absolute defenses, the OIG is warning providers that federal investigators will look past the paperwork to the actual intent behind the deal. In short, the agency is prioritizing the “spirit” of the law over the “checkbox” of compliance.
The Intent Gap: Why Stark Compliance Isn’t an AKS Shield
To understand the OIG’s warning, one must first understand the structural difference between the Stark Law and the Anti-Kickback Statute. While both aim to prevent improper financial incentives from influencing medical decisions, they operate on entirely different legal planes.
The Stark Law is a civil, strict liability statute. In the eyes of the law, intent is irrelevant. If a physician refers a patient to an entity with which they have a financial relationship that doesn’t fit a specific exception, the law has been broken—regardless of whether the physician intended to commit fraud or was simply unaware of the rule. Because of this, many providers view Stark compliance as the “high bar”; they assume that if they can clear the strict liability hurdle, they have naturally cleared the AKS hurdle.
The AKS is different. It is an intent-based statute. The core question is whether remuneration was offered, paid, solicited, or received “knowingly and willfully” to induce referrals. Because the AKS focuses on the why rather than just the what, an arrangement can be perfectly legal under the Stark Law’s strict rules but still be a criminal violation of the AKS if the underlying intent was to buy referrals.
The OIG illustrated this with a practical, real-world example involving “perks.” Under the Stark Law’s non-monetary compensation exception (42 C.F.R. § 411.357(k)), providers can offer non-cash items—such as tickets to a sporting event or entertainment—up to an annual cap, which stands at $535.00 for the 2026 calendar year. While these tickets might satisfy the Stark Law, the AKS has no such “small gifts” safe harbor. If those same tickets are given with the intent to reward a physician for sending patients to a specific lab or hospital, the OIG warns that the AKS could still be violated.
The ‘Fair Market Value’ Fallacy
Perhaps more disruptive to current industry practice is the OIG’s clarification on Fair Market Value (FMV). In many boardrooms and compliance offices, an FMV report is viewed as the “gold standard” of protection. The assumption is that if a payment is not excessive, it cannot be a kickback.
In the new FAQ No. 17, the OIG unequivocally rejects this notion. The agency points out a glaring fact: the text of the Anti-Kickback Statute does not even use the term “fair market value.” While FMV is often a required element to qualify for a specific AKS “safe harbor,” it is not a standalone defense. An arrangement can be priced exactly at market rate and still be an illegal kickback if the primary purpose of the payment is to induce referrals.
The OIG is urging providers to shift their focus toward “commercial reasonableness.” This means asking a critical question: Would this arrangement exist if there were no referrals involved? If a hospital pays a physician for a consulting role at a fair market rate, but the physician does no actual consulting and the only “value” they provide is a stream of referrals, the FMV payment is merely a vehicle for a kickback.
| Feature | Stark Law | Anti-Kickback Statute (AKS) |
|---|---|---|
| Nature of Law | Civil / Strict Liability | Criminal and Civil / Intent-Based |
| Role of Intent | Irrelevant to liability | Central to the violation |
| FMV Status | Often a requirement for exceptions | A best practice, but not a standalone defense |
| Primary Focus | Financial relationships/referrals | Remuneration to induce referrals |
What This Means for Healthcare Organizations
The simultaneous release of these FAQs suggests the OIG is tired of seeing the same defenses used in enforcement actions. For compliance officers, the takeaway is that documentation is no longer enough; they must now document the rationale.
Organizations are encouraged to move beyond simple FMV appraisals and instead build a “totality of the circumstances” file for every major financial arrangement. This includes documenting the legitimate business purpose of the deal and ensuring that every stream of payment satisfies every single condition of an applicable safe harbor, rather than just the pricing requirement.
For those navigating “close-to-the-line” arrangements, the OIG continues to point toward the Advisory Opinion process. Unlike the FAQs, which provide general guidance and are not legally binding, an Advisory Opinion provides a specific, binding analysis of a particular arrangement, offering the only true certainty in a shifting regulatory landscape.
Disclaimer: This article is for informational purposes only and does not constitute legal advice. Healthcare organizations should consult with qualified legal counsel to ensure compliance with federal and state fraud and abuse laws.
As the OIG continues to expand its FAQ channel—a resource first opened in 2023—the industry should expect further clarifications on the Beneficiary Inducements civil monetary penalty and other enforcement priorities. The next major checkpoint for providers will be the upcoming annual adjustment of non-monetary compensation caps and the release of the OIG’s next Work Plan, which typically outlines the agency’s specific audit targets for the coming year.
Do you think the OIG is overreaching, or is this necessary clarity for a complex industry? Share your thoughts in the comments below.
